SCHEMBL3081703

SCHEMBL3081703

O=C(O)c1ccn2nccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.47
HTT P42858 1/20 0.43
NAMPT P43490 1/20 0.43
KDM4C Q9H3R0 7/20 0.41
KDM5A P29375 5/20 0.41
KDM5B Q9UGL1 5/20 0.41
KDM4E B2RXH2 2/20 0.40
KDM6B O15054 2/20 0.40
KDM4A O75164 2/20 0.40
KDM5C P41229 2/20 0.40
KDM2A Q9Y2K7 2/20 0.40
KDM3A Q9Y4C1 2/20 0.40
TET3 O43151 1/20 0.40
BBOX1 O75936 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
ASPH Q12797 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
TET2 Q6N021 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176055 0.84 ESR1 (0.46) ESR1NAMPTKDM4EALDH1A1MAPT
SCHEMBL3089155 0.84 ESR1 (0.43) ESR1NAMPTMAPTRIPK1SCN5A
Hydrochloric Acid SCHEMBL30427215 0.82 ESR1 (0.43) ESR1NAMPTMAPTRIPK1SCN5A
SCHEMBL31205259 0.82 ESR1 (0.45) ESR1HTTNAMPTALDH1A1MAPT
SCHEMBL15762373 0.81 ESR1 (0.44) ESR1HTTNAMPTRIPK1SCN5A
SCHEMBL3642134 0.80 JMJD6 (0.44) ESR1HTTNAMPTKDM4CKDM5A
SCHEMBL30980395 0.80 AOC2 (0.50) ESR1HTTNAMPTKDM5AKDM4E
SCHEMBL15718194 0.78 RAB9A (0.51) NAMPTMAPTHTR1ADRD2DRD1
SCHEMBL24419196 0.78 NR4A2 (0.44) ESR1HTTNAMPTKDM4CKDM5A
SCHEMBL24419077 0.76 ESR1 (0.38) ESR1NAMPTKDM4ERIPK1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
EP-4727940-A1 DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF Linkcure Therapeutics (KY) 2026-04-22 EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4695248-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES Syngenta Crop Protection AG (CH) 2026-02-18 EP disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
WO-2024255810-A1 DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD (CN) 2024-12-19 WO disclosed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 WO disclosed
WO-2024213663-A1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-10-17 WO disclosed
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2012-10-11 US disclosed
WO-2012137089-A1 PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES PFIZER LIMITED (GB) 2012-10-11 WO disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP disclosed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof GRIN2A, GRIN2C, GRIN1 ESR1 1069/4885HTT 4207/4885NAMPT 862/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ESR1 2999/4885HTT 3651/4885NAMPT 4738/4885
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD ESR1 3218/4885HTT 4419/4885NAMPT 160/4885
US-20120258950-A1 PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS DMPK, DTYMK, MUSK ESR1 3891/4885HTT 3196/4885NAMPT 619/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 ESR1 1948/4885HTT 3617/4885NAMPT 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.